Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurontin Off-Label Use Needs Prior Authorization Under Fla. Medicaid Plan

Executive Summary

Prior authorization for off-label use of Pfizer's Neurontin would save the Florida Medicaid program $7 mil., the FY 2004-2005 budget proposal states

You may also be interested in...



Zyprexa Removal From Florida Medicaid Drug List Recommended By P&T Cmte

Use of Lilly's antipsychoticZyprexa would require prior authorization under Florida's Medicaid program should the state approve recommendations by a pharmacy & therapeutics committee

Zyprexa Removal From Florida Medicaid Drug List Recommended By P&T Cmte

Use of Lilly's antipsychoticZyprexa would require prior authorization under Florida's Medicaid program should the state approve recommendations by a pharmacy & therapeutics committee

Geodon, Abilify Have Low Diabetes Risk, ADA Says; Lilly Disagrees

An American Diabetes Association "consensus" statement on antipsychotics and the risk of diabetes may help Pfizer and Bristol-Myers Squibb make the case to FDA to exempt Geodon and Abilify from class labeling

Related Content

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel